Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma

Domenica Lorusso, Maria Mancini, Italo Sarno, Antonio Lambiase, Francesco Raspagliesi

Research output: Contribution to journalArticlepeer-review


Ovarian cancer (OC) is the most deadly gynaecological cancer. Despite surgery and first-line chemotherapy, between 60 % and 70 % of OC patients will recur with poor prognosis. Several studies suggest anti-tumour activity of tumour necrosis factor (TNF) when given systematically, but the high toxicity of the drug has limited its use. NGR-human TNF (hTNF) consists of TNF coupled with the peptide NGR that selectively binds to CD13, which is overexpressed on tumour blood vessels. NGR-hTNF is able to increase the intratumoural doxorubicin distribution by altering tumour vasculature. The activity and toxicity profile of NGR-hTNF-doxorubicin combination in recurrent OC will be described.

Original languageEnglish
Pages (from-to)9
Number of pages1
JournalEuropean Oncology and Haematology
Issue number1
Publication statusPublished - 2012


  • Doxorubicin
  • NGR-hTNF
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma'. Together they form a unique fingerprint.

Cite this